KalVista Pharmaceuticals Inc

KalVista’s chief development officer buys 1,774 shares, signaling confidence before EKTERLY’s AACC data—insider activity, social‑media buzz, and a $758 M market cap reveal.

KalVista insider buying signals CEO confidence in its biotech pipeline – a cautious, long‑term vote that may boost investor optimism.

KalVista CEO’s new share purchase signals confidence in EKTERLY and a promising oral protease‑inhibitor pipeline, hinting at future upside.